DCDamian M. Cummings

Damian M. Cummings

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Damian M. Cummings has a total of 282 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatially Resolved Microglial Expression Around Aβ Plaques in Human Alzheimer’s Disease Tissue

    by Jack I. Wood, Georgia Ppasia, Paul Rolland-Du-Roscoat, Sneha Desai, Shamim Choudhury, Aya Balbaa, Daria Gavriouchkina, Modesta Blunskyte-Hendley, John Hardy, Damian M. Cummings, et al.

    Summary: Using microglia-enriched spatial transcriptomics on human Alzheimer’s disease tissue, we identify distinct gene expression changes across microglia located in direct contact with plaques, in periplaque regions, and in areas distant from plaques. We define a group of plaque contact–only microglial (PCOM) genes whose expression increases exclusively in microglia directly contacting plaques. These genes show significant overlap with previously reported gene sets, suggesting that many of the well-characterised disease-associated microglia (DAM) and other AD-related gene-expression signatures are only upregulated when microglia contact plaques. We further identify distinct co-expression networks associated with disease-relevant covariates, including an immune module linked to APOE genotype and a synaptic–mitochondrial module negatively associated with Braak stage. Finally, we compare the human dataset to our previously published data from 18-month-old App NL-F mice, generated using the same experimental paradigm and demonstrate cross-species concordance in gene expression particularly within plaque-contacting microglia.

  • Open Access

    The Microglial Trem2 R47H Alzheimer's Disease Risk Variant Does Not Detectably Alter Hippocampal Synaptic Transmission in Young Mice

    by Abdulaziz Aljawder, Hedaythul Choudhury, Damian M Cummings, Jack Wood, Frances A. Edwards

    The rare R47H variant of the microglial TREM2 gene increases Alzheimers disease (AD) risk, but its effects on early hippocampal circuitry remain unclear. Trem2 has been reported to be important for microglial-dependent refinement of excitatory synaptic circuits in development. We hypothesized that loss of TREM2 function might result in changes in circuitry due to reduced microglial ability to prune inactive synapses and that this could predispose individuals to later disease. We compared basal synaptic transmission and synaptic density in 3-week-old WT and homozygous Trem2 R47H knockin mice, using in vitro patch clamp recordings and Bassoon-Homer1 immunohistochemistry. Basal synaptic activity, miniature excitatory events, and evoked release probability were unchanged. Synapse density in CA1 and CA3 showed substantial between-mouse variability but no evidence of genotype or regional differences. This variable CA1 synapse density was positively correlated with CA1 miniature excitatory event frequency. Although between-mouse variability in synaptic density could mask subtle changes, these data indicate that early effects of Trem2 R47H in these mice are not sufficient to produce a consistent change in early postnatal hippocampal excitatory synapse density or basal synaptic transmission under these conditions. This supports the view that TREM2-linked AD risk may act primarily through context-dependent mechanisms that become relevant with ageing, neuroinflammatory challenge, or AD pathology.

  • Open Access

    Isotope Encoded chemical Imaging Identifies Amyloid Plaque Age Dependent Structural Maturation, Synaptic Loss, and Increased Toxicity

    by Jack I. Wood, Maciej Dulewicz, Junyue Ge, Katie Stringer, Alicja Szadziewska, Sneha Desai, Srinivas Koutarapu, Haady B. Hajar, Kaj Blennow, Henrik Zetterberg, et al.

    It is of critical importance to our understanding of Alzheimer’s disease (AD) pathology to determine how key pathological factors are interconnected and implicated in nerve cell death, clinical symptoms, and disease progression. The formation of extracellular beta-amyloid (Aβ) plaques is the major pathological hallmark of AD and Aβ has been suggested to be a critical inducer of AD, driving disease pathogenesis. Exactly how Aβ plaque formation begins and how ongoing plaque deposition proceeds and initiates subsequent neurotoxic mechanisms is not well understood. The primary aim of our research is to elucidate the biochemical processes underlying early Aβ plaque formation in brain tissue. We recently introduced a chemical imaging paradigm based on mass spectrometry imaging (MSI) and metabolic isotope labelling to follow stable isotope labelling kinetics (iSILK) in vivo to track the in vivo build-up and deposition of Aβ. Herein, knock-in Aβ mouse models ( App NL-F ) that develop Aβ pathology gradually are metabolically labeled with stable isotopes. This chemical imaging approach timestamps amyloid plaques during the period of initial deposition allowing the fate of aggregating Aβ species from before and during the earliest events of plaque pathology through plaque maturation to be tracked. To identify the molecular and cellular response to plaque maturation, we integrated iSILK with single plaque transcriptomics performed on adjacent tissue sections. This enabled changes in gene expression to be tracked as a function of plaque age (as encoded in the Aβ peptide isotopologue pattern) distinct from changes due to the chronological age or pathological severity. This approach identified that plaque age correlates negatively with gene expression patterns associated with synaptic function as early as in 10-month-old animals but persists into 18 months. Finally, we integrated hyperspectral confocal microscopy into our multiomic approach to image amyloid structural isomers, revealing a positive correlation between plaque age and amyloid structural maturity. This analysis identified three categories of plaques, each with a distinct impact on the surrounding microenvironment. Here, we identified that older, more compact plaques were associated with the most significant synapse loss and toxicity. These data show how isotope-encoded MS imaging can be used to delineate Aβ toxicity dynamics in vivo. Moreover, we show for the first time a functional integration of dynamic MSI, structural plaque imaging and whole genome-wide spatial transcriptomics at the single plaque level. This multiomic approach offers an unprecedented combination of temporal and spatial resolution enabling a description of the earliest events of precipitating amyloid pathology and how Aβ modulates synaptotoxic mechanisms.


  • Open Access

    Sodium channel inhibitors alter the progress of tangle development in a mouse model of dementia

    by Chloe M. Hall, Martha Roberts, Roshni A. Desai, Damian M. Cummings, Jamie Bilsland, Paul Whiting, Kenneth J. Smith, Frances A Edwards

    Sodium channel inhibitors have been reported to protect against a range of neuroinflammatory and neurodegenerative diseases. Here the effect of chronic administration of two Na + channel inhibitors with different mechanisms of action, phenytoin and GS967 are tested in mouse models of different stages of Alzheimer’s disease. Subtle changes in the distribution of plaque sizes were observed in App NLGF/NLGF mouse at 3 months of age, after being fed control or drug-supplemented chow from weaning onwards, with phenytoin treatment resulting in a significant increase in the frequency of the smallest plaques and a decrease in large plaques. The later pathology of neurofibrillary tangles was studied, in old age, by supplementing the food of transgenic mice with a P301L mutation in Tau. Chronic administration of Na + inhibitors from 15 months of age resulted in a decrease in the density of MC1-positive neurofibrillary tangles, possibly due to effects on microglial Na + channels. The density of microglial cells was strongly correlated with the density of neurofibrillary tangles but only in mice treated with the Na + inhibitors.

  • Open Access

    Co-design for Heterogeneous Integration

    by Erica Douglas, Julia Deitz, Timothy Ruggles, Daniel Perry, Damion Cummings, Mark Rodriguez, Nichole Valdez, Brad Boyce

    As scaling for CMOS transistors asymptotically approaches the end of Moore's Law, the need to push into 3D integration schemes to innovate capabilities is gaining significant traction. Further, rapid development of new semiconductor solutions, such as heterogeneous integration, has turned the semiconductor industry's consistent march towards next generation products into new arenas. In 2018, the Department of Energy Office of Science (DOE SC) released their "Basic Research Needs for Microelectronics," communicating a strong push towards "parallel but intimately networked efforts to create radically new capabilities,"1 which they have coined as "co-design." Advanced packaging and heterogeneous integration, particularly with mixed semiconductor materials (e.g., CMOS FPGAs & GaN RF amplifiers) is a realm ripe for applicability towards DOE SC's co-design call to action. In theory, development occurring at all scales across the semiconductor ecosystem, particularly across disciplines that are not traditionally adjacent, should significantly accelerate innovation. In reality, co-design requires a paradigm shift in approach, requiring not only interconnected parallel development. Further, accurate ground truth data during learning cycles is critical in order to effectively and efficiently communicate across disparate disciplines and advise design iterations across the microelectronics ecosystem. This talk will outline three orthogonal facets towards co-design for HI: (1) on-going efforts towards development of materials characterization and failure analysis techniques to enable accurate evaluation of materials and heterogeneously integrated components, (2) development of artificial intelligence & machine learning algorithms for large scale, high throughput process development and characterization, and (3) development of capabilities for rapid communication and visualization of data across disparate disciplines.

  • Open Access

    Upregulation of Trem2 expression occurs exclusively on microglial contact with plaques

    by Jack Wood, Eugenia Wong, Ridwaan Joghee, Aya Balbaa, Karina S. Vitanova, Alison Vanshoiack, Stefan-Laural J. Phelan, Francesca Launchbury, Sneha Desai, Takshashila Tripathi, et al.

    Using spatial cell-type-enriched transcriptomics, we compare plaque-induced gene (PIG) expression in microglia touching plaques, neighboring plaques, and far from plaques in 18-month-old APP NLF/NLF knock-in mice with and without the Alzheimer’s disease risk mutation Trem2 R47H/R47H . We report that, in App NLF/NLF mice, expression of 35/55 PIGs, is exclusively upregulated in microglia that are touching plaques. In 7 PIGs including Trem2 this upregulation is prevented by the Trem2 R47H/R47H mutation. Unlike in young mice, knockin of the Trem2 R47H/R47H mutation does not significantly decrease the Trem2 expression but decreases protein levels by 20% in the absence of plaques. On plaques, despite the mutation preventing increased gene expression, TREM2 protein levels increased by 1.6-fold (compared to 3-fold with Trem2 WT/WT ) and microglial density increased 20-fold compared to 30-fold. Hence microglia must touch plaques before Trem2 gene expression is increased but small changes in protein expression can increase microglia density without a change in gene expression.

  • Open Access

    Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia

    by Diana P. Benitez, Shenyi Jiang, Jack Wood, Rui Wang, Chloe M. Hall, Carlijn Peerboom, Natalie Wong, Katie M. Stringer, Karina S. Vitanova, Victoria C. Smith, et al.

    Background: Microglia are active modulators of Alzheimer’s disease but their role in relation to amyloid plaques and synaptic changes due to rising amyloid beta is unclear. We add novel findings concerning these relationships and investigate which of our previously reported results from transgenic mice can be validated in knock-in mice, in which overexpression and other artefacts of transgenic technology are avoided. Methods: AppNL-F and AppNL-G-F knock-in mice expressing humanised amyloid beta with mutations in App that cause familial Alzheimer’s disease were compared to wild type mice throughout life. In vitro approaches were used to understand microglial alterations at the genetic and protein levels and synaptic function and plasticity in CA1 hippocampal neurones, each in relationship to both age and stage of amyloid beta pathology. The contribution of microglia to neuronal function was further investigated by ablating microglia with CSF1R inhibitor PLX5622. Results: Both App knock-in lines showed increased glutamate release probability prior to detection of plaques. Consistent with results in transgenic mice, this persisted throughout life in AppNL-F mice but was not evident in AppNL-G-F with sparse plaques. Unlike transgenic mice, loss of spontaneous excitatory activity only occurred at the latest stages, while no change could be detected in spontaneous inhibitory synaptic transmission or magnitude of long-term potentiation. Also, in contrast to transgenic mice, the microglial response in both App knock-in lines was delayed until a moderate plaque load developed. Surviving PLX5266-depleted microglia tended to be CD68-positive. Partial microglial ablation led to aged but not young wild type animals mimicking the increased glutamate release probability in App knock-ins and exacerbated the App knock-in phenotype. Complete ablation was less effective in altering synaptic function, while neither treatment altered plaque load. Conclusions: Increased glutamate release probability is similar across knock-in and transgenic mouse models of Alzheimer’s disease, likely reflecting acute physiological effects of soluble amyloid beta. Microglia respond later to increased amyloid beta levels by proliferating and upregulating Cd68 and Trem2. Partial depletion of microglia suggests that, in wild type mice, alteration of surviving phagocytic microglia, rather than microglial loss, drives age-dependent effects on glutamate release that become exacerbated in Alzheimer’s disease.


  • Open Access

    Additive manufacturing of multielectrode arrays for biotechnological applications

    by Amelia V. Edwards, Christopher Hann, Henry Ivill, Hanna Leeson, Larysa Tymczyszyn, Damian M. Cummings, Mark D. Ashton, Garry R. Harper, Diane T. Spencer, Wan Li Low, et al.

    Multielectrode arrays (MEAs) are electrical devices that transduce (record/deliver) cellular voltage signals. Commercially available MEAs are expensive and here we provide proof of concept for the application of an additive manufacturing approach to prepare inexpensive MEAs and demonstrate their ability to interact with brain tissue ex vivo.


  • Open Access

    Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions

    by Wenfei Liu, Orjona Taso, Rui Wang, Sevinc Bayram, Andrew C Graham, Pablo Garcia-Reitboeck, Anna Mallach, William D Andrews, Thomas M Piers, Juan A Botia, et al.

    Genome-wide association studies have reported that, amongst other microglial genes, variants in TREM2 can profoundly increase the incidence of developing Alzheimer’s disease (AD). We have investigated the role of TREM2 in primary microglial cultures from wild type mice by using siRNA to decrease Trem2 expression, and in parallel from knock-in mice heterozygous or homozygous for the Trem2 R47H AD risk variant. The prevailing phenotype of Trem2 R47H knock-in mice was decreased expression levels of Trem2 in microglia, which resulted in decreased density of microglia in the hippocampus. Overall, primary microglia with reduced Trem2 expression, either by siRNA or from the R47H knock-in mice, displayed a similar phenotype. Comparison of the effects of decreased Trem2 expression under conditions of lipopolysaccharide (LPS) pro-inflammatory or IL-4 anti-inflammatory stimulation revealed the importance of Trem2 in driving a number of the genes up-regulated in the anti-inflammatory phenotype. RNA-seq analysis showed that IL-4 induced the expression of a program of genes including Arg1 and Ap1b1 in microglia, which showed an attenuated response to IL-4 when Trem2 expression was decreased. Genes showing a similar expression profile to Arg1 were enriched for STAT6 transcription factor recognition elements in their promoter, and Trem2 knockdown decreased levels of STAT6. LPS-induced pro-inflammatory stimulation suppressed Trem2 expression, thus preventing TREM2’s anti-inflammatory drive. Given that anti-inflammatory signaling is associated with tissue repair, understanding the signaling mechanisms downstream of Trem2 in coordinating the pro- and anti-inflammatory balance of microglia, particularly mediating effects of the IL-4-regulated anti-inflammatory pathway, has important implications for fighting neurodegenerative disease.


  • Dementia associated with disorders of the basal ganglia

    by Karina S. Vitanova, Katie M. Stringer, Diana P. Benitez, Jonathan Brenton, Damian M. Cummings

    Dementia is now the leading cause of death in the United Kingdom, accounting for over 12% of all deaths and is the fifth most common cause of death worldwide. As treatments for heart disease and cancers improve and the population ages, the number of sufferers will only increase, with the chance of developing dementia doubling every 5 years after the age of 65. Finding an effective treatment is ever more critical to avert this pandemic health (and economic) crisis. To date, most dementia‐related research has focused on the cortex and the hippocampus; however, with dementia becoming more fully recognized as aspects of diseases historically categorized as motor disorders (e.g., Parkinson's and Huntington's diseases), the role of the basal ganglia in dementia is coming to the fore. Conversely, it is highly likely that neuronal pathways in these structures traditionally considered as spared in Alzheimer's disease are also affected, particularly in later stages of the disease. In this review, we examine some of the limited evidence linking the basal ganglia to dementia.